Here you will find all our clinical education resources from articles to recorded webinars, all supporting equitable access to funded medicines.
Your patient uses gliclazide and insulin but could still benefit from the additional cardiovascular and renal protections of empagliflozin. How would you manage the change in treatment?
This case study is particularly relevant to prescribers. It originally appeared in the 3 March 2021 issue of New Zealand Doctor Rata Aotearoa and has been republished with permission.
Current management of type 2 diabetes includes two new classes of medication, SGLT2 inhibitors and GLP-1 receptor agonists, where clinically indicated. This article was published in the April 2021 edition of Kai Tiaki. It has been edited specifically for our nursing readership from an article that appeared in New Zealand Doctor and Pharmacy Today late in 2020.
This article is endorsed by the College of Nurses Aotearoa (NZ) Inc.
Capture, a new online tool, will help He Ako Hiringa members keep track of what they’re learning online.
Clicking the Capture button at the bottom of each educational piece will create a record of the time taken to read, watch or listen to that content. Members will also be able to record their thoughts and reflections on the content, creating a Capture Record that can then be downloaded and used as a record of learning.
Health inequities in the detection and management of diabetes and its associated health outcomes are significant concerns in New Zealand. The first step to addressing inequitable health outcomes is knowing that they exist.
Read the HAH bulletin to find out more.
In this video, Dr Paul discusses the changes to type 2 diabetes care in 2021, including when and how to use SGLT2 inhibitors and GLP-1 agonists. You can watch the webinar here or in ELearning.
Downloadable empagliflozin patient information and a recent slide presentation can be found within this article.
If you're having trouble pronouncing the name of the newly funded SGLT2 inhibitor for type 2 diabetes, you're not the only one! Watch our video guide to learn how to pronounce empagliflozin.
A new study from the University of Auckland examined ethnic variation in the quality use of medicines between Māori and non-Māori older adult populations. Simon Maude from New Zealand Doctor Rata Aotearoa spoke to the study's lead author Joanna Hikaka and investigated the impact of this research.
We are pleased to be providing educational content to the New Zealand Nurses Organisation for publication in Kai Tiaki Nursing New Zealand. Our first contribution, "How to change lives: Prescribing equity through better use of medicines", appears in the February issue of Kai Tiaki Nursing New Zealand and is part of a course endorsed by CNA(NZ) for 1.5 hours of professional development.
To complete the course, click here to go to ELearning.
Inequities exist in all aspects of diabetes care. In this article, Alesha Smith outlines some examples, proposes some actions, and explains where the new medicines fit in.
This activity has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 0.5 CME credits for the General Practice Educational Programme (GPEP) and Continuing Professional Development (CPD) purposes.
Late last year, PHARMAC announced the SGLT2 inhibitor empagliflozin (Jardiance®) and empagliflozin with metformin (Jardiamet®) will be funded for the treatment of type 2 diabetes under Special Authority.
Find out all you need to know about the Special Authority criteria.
In this webinar, Alesha Smith discusses the development of He Ako Hiringa and presents our new interactive data tool, EPiC. You can watch this webinar here or in ELearning.
In this webinar, Dr Rinki Murphy discusses the issue of inequity in diabetes care. You can watch this webinar here or in ELearning.